NCT00933231 - Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts | Biotech Hunter

Enrollment

281

Participants

Timeline

Start Date

August 17, 2009

Primary Completion Date

May 11, 2015

Study Completion Date

April 3, 2018

Conditions

Kidney Transplantation

Interventions

DRUG

tacrolimus

Standard dose, Oral

DRUG

tacrolimus

Low dose, Oral

BIOLOGICAL

Simulect

DRUG

Cellcept

Oral

DRUG

Corticosteroids

IV and Oral

DRUG

Ramipril

Oral

DRUG

Irbesartan

Oral

Trial Locations (13)

T2N 2T9

Site CA133 Foothills Medical Centre, Calgary

T6G 2B7

Site CA54 University of Alberta Hospital, Edmonton

R3A 1R9

Site CA141 Health Sciences Centre, Winnipeg

B3H 1V7

Site CA114 Capital District Health Authority- QEII Health Sciences Centre, Halifax

L8N 4A6

Site CA150 St. Joseph's Healthcare, Hamilton

N6A 5A5

Site CA27 London Health Sciences Centre, London

M5C 2T2

Site CA165 St. Michael's Hospital, Toronto

H1T 2M4

Site CA238 Hôpital Maisonneuve-Rosemont, Montreal

H2L 4M1

Site CA172 Hôpital Notre-Dame du CHUM, Montreal

H4A 3J1

Site CA144 McGill University Health Centre, Montreal

G1R 2J6

Site CA64 Centre Hospitalier Universitaire de Québec- L'Hôtel-dieu de Québec, Québec

J1H 5N4

Site CA116 Centre Hospitalier Universitaire de Sherbrooke- Hôpital Fleuirmont, Sherbrooke

S7V 0Z9

Site CA142 St. Paul's Hospital, Saskatoon